Log in
Enquire now
Intrexon

Intrexon

A life sciences company researching and developing bio-therapeutic control systems.

OverviewStructured DataIssuesContributors

Contents

Acquisitions GenVec TimelineTable: Funding RoundsTable: ProductsTable: AcquisitionsTable: SBIR/STTR AwardsTable: PatentsTable: Further ResourcesReferences
dna.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Technology
Technology
Loading...
Loading...
Loading...
Biology
Biology
Biotechnology
Biotechnology
Synthetic biology
Synthetic biology
Location
Germantown, Anne Arundel County, Maryland
Germantown, Anne Arundel County, Maryland
Germantown, Maryland
Germantown, Maryland
B2X
B2C
B2C
B2B
B2B
3
AngelList URL
angel.co/intrexon
Legal Name
Intrexon Corporation
Subsidiary
‌
Actobio Therapeutics
Precigen
Precigen
Trans Ova Genetics
Trans Ova Genetics
Oxitec
Oxitec
Number of Employees (Ranges)
501 – 1,0003
Email Address
publicrelations@intrexon.com
Phone Number
+15409610725
Full Address
20358 Seneca Meadows Parkway Germantown, MD 20876
Investors
‌
Randal J. Kirk
Third Security
Third Security
Founded Date
1998
3
Total Funding Amount (USD)
227,092,352
Latest Funding Round Date
November 16, 2012
Stock Symbol
XON
Exchange
New York Stock Exchange
New York Stock Exchange
Glassdoor ID
275054
Latest Funding Type
‌
Series F
Wellfound ID
intrexon

Other attributes

Company Operating Status
Active
Wikidata ID
Q43079701

Intrexon is a gene expression and regulation company focused on control of cells and organisms that is headquartered in Germantown, Maryland and was founded in 1998. The company is developing technology for biological systems across four major biology classes - Microbes, Plants, Animals, Human Cells - to protect the environment, promote health, and feed the growing populations of humans and animals. The company is also developing gene and cell therapies using precision immunology. Intrexon is using several technologies to develop their products which give them the capability to precisely control gene expression, design and engineer biosystems, and engineering gene function and delivery.

Acquisitions
GenVec

On January 23, 2017 Intrexon acquired a gene therapy company called GenVec for approximately $15.9 million. The deal gave stockholders of GenVec 0.297 of an Intrexon share for each share of GenVec common stock based on Intrexon's five-day weighted average as of January 23, 2017.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Intrexon

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.